Changes Clinical Practice: A biopsy and hair root examination should be performed in cases of sudden-onset diffuse alopecia. This article is interesting because of the illustration that acute diffuse ...
Alopecia areata equally affects men and women, usually at age 20-40 years. The lifetime risk of alopecia areata expression in the general population has been estimated to be 1.7%. [19] The disease ...
"We are pleased that rezpegaldesleukin has been granted Fast Track designation for the treatment of alopecia areata, adding to its Fast Track designation in atopic dermatitis," said Jonathan Zalevsky, ...
Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, rezpegaldesleukin, for treating individuals with severe-to-very-severe ...
SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in ...
Alopecia areata Patients with psoriasis and alopecia areata (AA) should also be screened for underlying metabolic abnormalities. Patients with psoriasis and alopecia areata (AA) should also be ...
Despite years of rigorous training and experience, even the best dermatologists may miss a pediatric diagnosis, particularly for dermatologists who don't see as many pediatric patients. Some ...
The next in our series of quick quizzes in dermatology asks – what's causing patches of hair loss in this male patient in his ...
SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback